By Kailyn Rhone
Shares of Harrow slipped after the pharmaceutical company reported third-quarter results that missed analysts' expectations.
The stock closed down 25%, at $39.10, in after-hours trading Wednesday. For the year, shares are up 362%.
The Nashville company reported a third-quarter loss of $4.2 million, or 12 cents a share, compared with a loss of $4.4 million, or 13 cents a share, for the same period a year earlier. Analysts polled by FactSet expected a loss of five cents.
Revenue rose 44%, to $49.3 million. That fell short of the $52.8 million expected by analysts polled by FactSet.
Chief Executive Mark L. Baum said the company sees strong performance for the fourth quarter and expects "a record-breaking finish" for the year.
Write to Kailyn Rhone at kailyn.rhone@wsj.com
(END) Dow Jones Newswires
November 13, 2024 17:37 ET (22:37 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.